Conjugate Or Complex Includes Virus Or Componenet Thereof Patents (Class 424/196.11)
-
Publication number: 20110206725Abstract: The present invention provides a method for the purification of complexes comprising a stress protein complexed to a peptide or peptide fragment, from a source mixture, typically a cell lysate. The improved method of the invention provides for protein complexes to be purified using ion exchange based methods, without the need to use chemicals such as chaotropes and ampholytes. The purified complexes can be used as the immunogenic determinant in vaccine compositions for the treatment or prevention of infectious diseases or cancerous conditions.Type: ApplicationFiled: September 7, 2009Publication date: August 25, 2011Applicant: IMMUNOBIOLOGY LIMITEDInventors: Camilo Colaco, Kamram Salim
-
Publication number: 20110200633Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.Type: ApplicationFiled: April 23, 2010Publication date: August 18, 2011Applicant: THE TRUSTEES OF PRINCETON UNIVERSITYInventors: Thomas Shenk, Dai Wang
-
Patent number: 7998487Abstract: Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided.Type: GrantFiled: February 14, 2008Date of Patent: August 16, 2011Assignees: The Salk Institute for Biological Studies, The Scripps Research InstituteInventors: John Young, Anette Schneemann, Marianne Manchester, Kelly Dryden, John M. Marlett, Darly Joseph Manayani, Godfrey Jonah Anderson Rainey, Vijay Reddy, Marc E. Siladi, Heather M. Scobie, Diane Thomas, Mark Yeager
-
Patent number: 7998485Abstract: Methods of delivering a cargo moiety to a cell is provided according to embodiments of the present invention which includes contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and is internalized along with the cargo, delivering the cargo moiety to the cell. Particular methods provided by the present invention include induction or enhancement of sialoadhesin expression in a cell which naturally produces little or no sialoadhesin. Induction or enhancement of sialoadhesin expression includes transfection of a sialoadhesin expression construct and/or administration of an agent effective to induce or enhance sialoadhesin expression. Methods and compositions for stimulating an immune response in a subject are detailed. Particular methods and compositions for stimulating an immune response to a virus are provided by the present invention.Type: GrantFiled: May 11, 2007Date of Patent: August 16, 2011Assignee: Universiteit GentInventors: Hans Nauwynck, Peter Delputte
-
Patent number: 7988974Abstract: The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular carrier group fused to a gp41-derived DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1LA1 gp41 protein, or fragments, analogs or homologs of DP178. The invention further relates to the uses of such fusion peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.Type: GrantFiled: October 17, 2005Date of Patent: August 2, 2011Assignee: Duke UniversityInventors: Michael L. Greenberg, Thomas James Matthews, Chin-Ho Chen
-
Publication number: 20110171248Abstract: Disclosed are compositions and related methods that involve a synthetic nanocarrier that includes at least one peptide obtained from Human papillomavirus L1 or L2 capsid protein; wherein the peptide is coupled to an external surface of the synthetic nanocarrier.Type: ApplicationFiled: January 7, 2011Publication date: July 14, 2011Applicant: Selecta Biosciences, Inc.Inventors: Lynnelle Ann McNamee Pittet, Yun Gao, Charles Zepp, Grayson B. Lipford
-
Patent number: 7964196Abstract: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanocparticle drug delivery system is also provided.Type: GrantFiled: May 25, 2005Date of Patent: June 21, 2011Assignee: Chimeros, Inc.Inventors: Miguel de los Rios, Kenneth J. Oh
-
Patent number: 7959924Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The present invention provides, inter alia, a composition comprising a virus-like particle (VLP) and at least one antigen, wherein said antigen is a GIP protein or a GIP fragment linked to the VLP respectively. The invention also provides a method for producing the aforesaid composition. The compositions of this invention are useful in the production of vaccines, in particular, for the prevention and/or treatment of obesity and hereby, in particular, by inducing efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. Accordingly, the invention further provides for methods of treating and/or preventing obesity and other conditions.Type: GrantFiled: August 4, 2009Date of Patent: June 14, 2011Assignee: Cytos Biotechnology AGInventors: Martin F. Bachmann, Alma Fulurija, Philippe Saudan
-
Publication number: 20110129484Abstract: Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.Type: ApplicationFiled: April 17, 2009Publication date: June 2, 2011Inventors: Jeffrey A. Gelfand, Mark C. Poznansky, Pierre R. Leblanc, Svetlana E. Korochkina
-
Patent number: 7943139Abstract: A small peptide of 10 or 11 mers, when linked to an immunogenic moiety, can protect against naferious effects of Nef protein of HIV. The vaccine is not used to induce sterilizing immunity, but to block the ability of soluble Nef protein to induce apoptosis, and to therefore alleviate lymphocyte depletion and organ damage.Type: GrantFiled: January 7, 2005Date of Patent: May 17, 2011Assignee: Morehouse School of MedicineInventors: Vincent C. Bond, Michael Powel, Ming Bo Huang, Cleve James
-
Publication number: 20110110972Abstract: Compositions and methods for treating immune cells and activating immune responses are disclosed. The compositions comprise one or more optically active chiral cationic lipids.Type: ApplicationFiled: April 14, 2009Publication date: May 12, 2011Applicant: PDS BIOTECHNOLOGY CORPORATIONInventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya Toney Johnson, Gregory Conn, Frank Bedu-addo, Leaf Huang
-
Publication number: 20110097417Abstract: The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA linked thereto. Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against MelanA peptide analogues optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against the MelanA peptide analogues are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.Type: ApplicationFiled: May 11, 2009Publication date: April 28, 2011Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Vania Manolova, Edwin Meijerink, Karl G. Proba, Katrin Schwarz
-
Publication number: 20110076304Abstract: The invention relates to an adapter protein comprising a coxackievirus and adenovirus receptor (CAR) region and a human CD40 ligand and to the uses thereof for promoting adenoviral transduction of dendritic cells while at the same time promoting maturation of the DCs. The invention also relates to pharmaceutical compositions comprising said adapter protein and an adenovirus encoding an antigen and the uses thereof in a method for eliciting an immune response against the antigen encoded in said adenovirus as well as to antigen-loaded dendritic cells obtained the adaptor protein and an adenovirus and to the uses thereof in a method of eliciting an immune response against the antigen encoded in the adenovirus.Type: ApplicationFiled: May 19, 2009Publication date: March 31, 2011Applicants: PROYECTO DE BIOMEDICINA CIMA, S.L., THE UAB RESEARCH FOUNDATIONInventors: Alexander Pereboev, George Tsuladze, Igor Bogdashin, Itziar Echeverria Beistegui, Juan José Lasarte Sagastibelza, Jesùs Maria Prieto Valtueña, Pablo Sarobe Ugarriza
-
Patent number: 7914791Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.Type: GrantFiled: May 10, 1999Date of Patent: March 29, 2011Assignee: Trident Pharmaceuticals, Inc.Inventors: Timothy Raymond Hirst, Neil Andrew Williams, Andrew Morgan, Andrew Douglas Wilson, Lucy Amber Bird
-
Publication number: 20110070249Abstract: The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an A?PP epitope spanning the ?-secretase cleavage site of A?PP and a method for inducing an immune response against the ?-secretase cleavage site of A?PP using this immunizing composition. The present invention is also directed to antibodies against the ?-secretase cleavage site of A?PP and their use in a method for inhibiting the formation of amyloid ?.Type: ApplicationFiled: December 6, 2010Publication date: March 24, 2011Applicant: Ramot At Tel-Aviv University LTD.Inventor: Beka SOLOMON
-
Patent number: 7910110Abstract: The present invention relates to vaccines comprising a bacteriophage which has been engineered to express an immunogenic protein/peptide and wherein the surface of the bacteriophage has not been modified to contain proteins/peptides designed to target the phage to receptors on the surface of specific cell types.Type: GrantFiled: October 2, 2003Date of Patent: March 22, 2011Assignee: BigDNA LimitedInventors: John Bernard March, Jason Clark
-
Publication number: 20110064754Abstract: The present invention concerns methods and compositions for subunit-based vaccines for inducing immunity against poxvirus infections, such as smallpox. Preferred embodiments concern immunoconjugates comprising one or more subunit antigenic peptides attached to an antibody or fragment thereof that targets antigen-producing cells (APCs). More preferably, the antibody binds to HLA-DR and the antigenic peptide is from an immunomodulating factor, such as the viral IL-18 binding protein (vIL18BP). However, mixtures of antigenic peptides from different viral proteins may also be used. The vaccine is capable of inducing immunity against poxvirus without risk of disseminated infection in immunocompromised hosts or transmission to susceptible contacts.Type: ApplicationFiled: October 29, 2010Publication date: March 17, 2011Applicant: CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGYInventors: Alice P. Taylor, Boby Makabi-Panzu, David M. Goldenberg
-
Publication number: 20110027306Abstract: The present disclosure provides TC-83 VEE-derived replicons, alphaviral replicon particles and immunogenic compositions containing TC-83 alphaviral replicon particles which direct the expression of at least one antigen when introduced into a suitable host cell. The TC-83 VEE-derived ARPs described herein are improved in that they are subject to a lower vector-specific immune response than prior art ARPs.Type: ApplicationFiled: July 6, 2010Publication date: February 3, 2011Applicant: AlphaVax, Inc.Inventors: Jon O. Rayner, Jonathan F. Smith, Bolyn Hubby, Elizabeth A. Reap
-
Publication number: 20110014226Abstract: A method to identify small molecules useful as therapeutics and/or vaccines to prevent, alleviate or ameliorate a pathogenic infection or an autoimmune disorder. The method can be used to screen small molecule test compounds for the ability to disrupt particular antigen-antibody interactions of interest. In one embodiment, the antigen is a pathogen-derived antigen and the antibody decreases or inhibits virulence of the pathogen when bound to the antigen (e.g., a neutralizing antibody, antibody with serum bactericidal activity, etc.). In another embodiment, the antigen is a self-antigen (autoantigen) and the antibody is an autoantibody that is known to be associated with a pathological condition (e.g., autoimmune disorder). Compounds that bind to the antigen or antibody disrupt binding can be used as therapeutics to decrease or inhibit the autoimmune disorder.Type: ApplicationFiled: March 17, 2009Publication date: January 20, 2011Inventors: Michael J. Caulfield, Michael D. Miller, Joseph G. Joyce, Paul D. Zuck, Krista L. Getty, Vadim Dudkin, Elizabeth A. Ottinger
-
Publication number: 20100330115Abstract: The present invention includes compositions and methods for designing, making and using modular recombinant antibodies or fragments thereof with one half of a cohesin-dockerin pair that permits the rapid assembly of multivariant antigen conjugates.Type: ApplicationFiled: June 21, 2010Publication date: December 30, 2010Applicant: BAYLOR RESEARCH INSTITUTEInventors: Gerard Zurawski, Anne-Laure Flamar, Eynav Klechevsky
-
Publication number: 20100322962Abstract: A substituted Norovirus capsid protein monomer, having only the P-domain and called an antigen-Norovirus P-domain monomer, includes a foreign antigen inserted into one or more of three surface loops present on each P-domain monomer by molecular cloning. The antigen-P-domain monomer can assemble spontaneously into an octahedral form, called an antigen-Norovirus P-particle, that is composed of 24 copies of the antigen-P-domain monomer. Each substituted P-domain monomer will contain one to three copies of the foreign antigen, for a total of 24-72 antigen copies on each antigen-P-particle. The antigen-P-particle is useful in methods for diagnosing, immunizing and treating individuals infected with a foreign virus, for example Rotavirus, and can serve as a carrier for presentation of foreign antigens for development of novel vaccines against many infectious and non-infectious diseases. The substituted Norovirus P-particles can be readily produced in E.Type: ApplicationFiled: June 9, 2010Publication date: December 23, 2010Inventors: Xi Jiang, Ming Tan
-
Publication number: 20100316665Abstract: An antigen-presenting system (APS) comprising one or more enterobacterial antigens in combination with a papaya mosaic virus (PapMV) or a virus like particle (VLP) derived from papaya mosaic virus is provided. The PapMV or VLP included in the APS is capable of potentiating an immune response against said one or more enterobacterial antigens. The APS can be used, for example, as a vaccine against enterobacterial disease, such as typhoid fever. The one or more antigens comprised by the APS can be conjugated to a coat protein of the PapMV or PapMV VLP, or they may be non-conjugated (i.e. separate from the PapMV or PapMV VLP), or the APS can comprise both conjugated and non-conjugated antigens. Conjugation can be, for example, by genetic fusion with the coat protein, or binding via covalent, non-covalent or affinity means.Type: ApplicationFiled: January 28, 2008Publication date: December 16, 2010Inventors: Denis Leclerc, Constantino Roberto López-Macias, III
-
Patent number: 7833775Abstract: Free-living microbes are provided in which the nucleic acid has been modified so that the microbe is attenuated for proliferation and/or which comprise genetic mutations that attenuate the ability of the microbe to repair its nucleic acid. Methods of using the modified microbes for the loading, activation, and/or maturation of antigen-presenting cells are also provided. Vaccine compositions comprising the modified microbes and/or the antigen-presenting cells and methods of using the vaccines are also provided. The microbes may be further modified to include heterologous antigens, such as tumor antigens or infectious disease antigens, for use as a vaccine against cancer or infectious diseases.Type: GrantFiled: February 6, 2004Date of Patent: November 16, 2010Assignee: Aduro BioTechInventors: Thomas W. Dubensky, Jr., Dirk G. Brockstedt, John E. Hearst, David N. Cook
-
Publication number: 20100285055Abstract: The present invention relates to filovirus VLPs and their use in activating innate immunity, specifically natural killer cells, and in enhancing an immune response to an antigen in an animal.Type: ApplicationFiled: March 22, 2010Publication date: November 11, 2010Inventors: Sina Bavari, Kelly L. Warfield
-
Publication number: 20100278919Abstract: The present invention provides compositions and methods for targeting dendritic cells of the immune system. In particular, the compositions comprise carbon nanoparticles, optionally magnetic carbon nanoparticles comprising iron, which are preferentially endocytosed by dendritic cells compared to macrophages when contacted with a biological sample. The nanoparticles of the present invention may be functionalized to enhance delivery of biomolecules to dendritic cells.Type: ApplicationFiled: December 5, 2007Publication date: November 4, 2010Inventors: Ferencz S. Denes, Zsuzsanna Fabry, Matyas Sandor
-
Patent number: 7824669Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: July 14, 2009Date of Patent: November 2, 2010Assignee: Bolder Biotechnology, Inc.Inventors: George N. Cox, III, Daniel H. Doherty
-
Publication number: 20100260792Abstract: The present invention is directed to a chimeric papillomavirus virus-like particle (VLP) or capsomere including an L1 polypeptide and, optionally, an L2 polypeptide, and a respiratory syncytial virus (RSV) protein or polypeptide fragment thereof comprising a first epitope, where the RSV protein or polypeptide fragment thereof is attached to one or both of the L1 and L2 polypeptides. Chimeric proteins, genetic constructions, and recombinant vectors and host cells suitable for expression of the constructs and making of the chimeric VLPs or capsomeres are also disclosed. Use of the VLPs or capsomeres, or a pharmaceutical composition containing the same, is contemplated for inducing a protective immune response against RSV.Type: ApplicationFiled: October 22, 2008Publication date: October 14, 2010Applicant: UNIVERSITY OF ROCHESTERInventors: Yoshihiko Murata, Robert C. Rose, Edward E. Walsh, Ann R. Falsey
-
Patent number: 7811573Abstract: The present invention concerns a method for prophylactic and/or therapeutic vaccination and/or treatment and/or diagnosis of HIV/AIDS, other infectious diseases, inflammatory and angiogenic diseases and tumours which utilizes a biologically active HIV-1 Tat protein, fragments or derivates thereof, as a module with one or more of the following features: antigen, adjuvant and targeting-delivery system to specific antigen-presenting cells including dendritic cells, endothelial cells and macrophages. In particular, it is claimed that Tat can be used only in its biologically active form as an antigen combined with one or more other antigens, to prime or to boost protective immune responses against itself as well as other antigens and/or to selectively deliver these antigen(s) as well as active compounds to dendritic cells, endothelial cells and macrophages, due to its capability of targeting these A PC and of activating their maturation and functions and of increasing Th-1 type immune responses as an adjuvant.Type: GrantFiled: July 26, 2002Date of Patent: October 12, 2010Assignee: Istituto Superiore di Sanita'Inventor: Barbara Ensoli
-
Patent number: 7803379Abstract: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions.Type: GrantFiled: December 13, 2005Date of Patent: September 28, 2010Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Teresa Elisa Virginia Cabezon-Silva, Jean-Pol Cassart, Thierry Coche, Swann Romain Jean-Thomas Gaulis, Carlota Vinals Y De Bassols
-
Publication number: 20100221281Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.Type: ApplicationFiled: January 26, 2010Publication date: September 2, 2010Applicant: World Force Technologies, LLCInventors: Thomas W. Konowalchuk, Jack Konowalchuk
-
Publication number: 20100209449Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: April 23, 2010Publication date: August 19, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers, Malcolm L. Gefter
-
Patent number: 7767212Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens.Type: GrantFiled: March 17, 2006Date of Patent: August 3, 2010Assignee: Cytos Biotechnology AGInventors: Martin Bachmann, Monika Bauer, Klaus Dietmeier, Nicole Schmitz, Stephan Utzinger
-
Patent number: 7744898Abstract: Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.Type: GrantFiled: September 8, 2005Date of Patent: June 29, 2010Assignee: The Scripps Research InstituteInventor: Francis V. Chisari
-
Patent number: 7740860Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.Type: GrantFiled: March 13, 2006Date of Patent: June 22, 2010Assignee: The Wistar InstituteInventors: Walter Gerhard, Laszlo Otvos, Jr.
-
Publication number: 20100129395Abstract: The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.Type: ApplicationFiled: October 8, 2008Publication date: May 27, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. Bachmann, Patrik Maurer
-
Publication number: 20100119540Abstract: This invention relates to the field of vaccination and treatment or prevention diseases. In particular this invention relates to the treatment or prevention of diseases by inducing hapten-specific antibody responses in a vaccinated subject. The invention further provides a method for prevention or treatment of a disease by inducing hapten-specific antibodies in a subject comprising administering into said subject a composition comprising a virus-like particle of an RNA bacteriophage and at least one hapten linked thereto.Type: ApplicationFiled: April 18, 2008Publication date: May 13, 2010Inventors: Martin Bachmann, Patrik Maurer, Philipp Muller, Thomas Pfister, Wolfgang Renner
-
Publication number: 20100111995Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen of the invention, wherein said antigen of the invention is CCR5 of the invention, gastrin of the invention, CXCR4 of the invention, CETP of the invention or C5a of the invention. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of diseases in which the antigen of the invention mediates, or contributes to the condition, particularly for the treatment of AIDS, gastrointestinal cancers, coronary heart diseases or inflammatory diseases. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses.Type: ApplicationFiled: June 14, 2006Publication date: May 6, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. Bachman, Alain Tissot, Andrea Jegerlehner, Philippe Saudan, Yu Zou, Nicole Schmitz, Adrian Huber, Stephen Martin, Heather Hinton
-
Publication number: 20100092508Abstract: The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.Type: ApplicationFiled: December 22, 2008Publication date: April 15, 2010Applicant: Cytos Biotechnology AGInventors: Martin F. BACHMANN, Alain Tissot, Paul Pumpens, Indulis Cielens, Regina Renhofa
-
Publication number: 20100086584Abstract: The present disclosure generally relates to a composition comprising one or more peptides selected from influenza virus antigenic peptides M2e, HA0, BM2 and a M2e-BM2 fusion peptide in a composition with a cationic liposome delivery vehicle, and the use of these compositions as a universal vaccine against influenza A and/or B viral strains.Type: ApplicationFiled: September 18, 2009Publication date: April 8, 2010Applicant: Juvaris BioTherapeutics, Inc.Inventors: Bernadette Callejo, Tom Monath, Jeffery Fairman
-
Publication number: 20100074918Abstract: The present invention relates to the field of vaccines and in particular to combination vaccines and co-administration schedules. The present inventor discloses that overuse of CRM in paediatric vaccines can result in bystander immune interference to certain antigens and provide solutions to this problem.Type: ApplicationFiled: April 30, 2008Publication date: March 25, 2010Inventor: Jan Poolman
-
Publication number: 20100068222Abstract: Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.Type: ApplicationFiled: August 3, 2009Publication date: March 18, 2010Inventors: Philip A. Swain, Victoria C. Schad, Julia L. Greenstein, Mark A. Exley, Barbara S. Fox, Stephen P. Powers
-
Patent number: 7674469Abstract: This invention is directed to a vaccine and a method for using the vaccine to protect a feline from influenza virus infection. The vaccine comprises one or more antigens from one or more H3, N8, H7 or N7-type influenza viruses.Type: GrantFiled: October 25, 2007Date of Patent: March 9, 2010Assignee: Internet International B.V.Inventors: Nallakannu P. Lakshmanan, Melissa A. Lum, Frank J. Sterner, Frederick Randal Bethke
-
Publication number: 20100047271Abstract: The present invention relates generally to an immunogenic complex comprising a charged organic carrier and a charged antigen and, more particularly, a negatively charged organic carrier and a positively charged antigen, wherein the charged antigen is a polyprotein of Hepatitis C Virus (HCV), particularly the core protein of HCV, or a fragment thereof, or a fusion protein comprising the polyprotein or a fragment thereof. The complexes of the present invention are useful, inter alia, in vaccine compositions as therapeutic and/or prophylactic agents for facilitating the induction of immune responses, and in particular a cytotoxic T-lymphocyte response, in the treatment of a disease condition which results from an HCV infection.Type: ApplicationFiled: November 5, 2009Publication date: February 25, 2010Inventors: Debbi Drane, John Cox, Michael Houghton, Xavier Pallard
-
Publication number: 20100040646Abstract: Disclosed are split-core carrier substances which, as separate polypeptides, have the core N domain and the core C domain of the core protein of a hepatitis B virus and at least one foreign molecule against which an immune response is to be induced. According to the invention, the foreign molecule, especially the heterologous foreign amino acid sequence, is fused to the C terminus of the core N domain or to the N terminus of the core C domain and the core protein can form capsid-like particles. The invention also relates to the associated production method.Type: ApplicationFiled: July 12, 2007Publication date: February 18, 2010Applicant: Universitatsklinikum FreiburgInventors: Michael Nassal, Claudia Skamel, Andreas Walker
-
Publication number: 20100040645Abstract: The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual art hsp or a portion of an ATP binding domain of an hsp joined to the molecule. In one embodiment, the present invention relates to a method of treating HIV in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the molecule. Also encompassed by the present invention is a method of inducing a CD4+ independent CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule. The present invention also relates to a method of inducing a CD8+ CTL response in an individual comprising administering to the individual a portion of an ATP binding domain of an hsp joined to the molecule.Type: ApplicationFiled: March 9, 2009Publication date: February 18, 2010Inventors: Qian Huang, Joan F.L. Richmond, Bryan K. Cho, Deborah Palliser, Jianzhu Chen, Herman N. Eiser, Richard A. Young
-
Patent number: 7662398Abstract: Therapeutic methods and microorganisms therefor are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proliferating tissues, particularly tumors, to produce selected proteins and other products. Vaccines containing the microorganisms are provided. Combinations of the microorganisms and anti-cancer agents and uses thereof for treating cancer also are provided.Type: GrantFiled: September 27, 2006Date of Patent: February 16, 2010Assignee: Genelux CorporationInventors: Aladar A. Szalay, Tatyana Timiryasova, Yong A. Yu, Qian Zhang
-
Publication number: 20100034847Abstract: Various improvements to vaccines that include a serogroup C meningococcal conjugate antigen, including: (a) co-administration with acellular B. pertussis antigen; (b) co-administration with an inactivated poliovirus antigen; (c) supply in a kit together with a separate pneumococcal conjugate component, which may be in a liquid form; and (d) use in combination with a pneumococcal conjugate antigen but without an aluminium phosphate adjuvant. A kit may have: (a) a first immunogenic component that comprises an aqueous formulation of a conjugated capsular saccharide from Streptococcus pneumoniae; (b) a second immunogenic component that comprises a conjugated capsular saccharide from Neisseria meningitidis serogroup C.Type: ApplicationFiled: September 1, 2006Publication date: February 11, 2010Inventor: Astrid Borkowski
-
Publication number: 20090324634Abstract: The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by Trypanosoma protozoa. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.Type: ApplicationFiled: April 28, 2008Publication date: December 31, 2009Inventors: Elisabeth Knapp, Vidadi Yusibov
-
Publication number: 20090317422Abstract: The present invention provides a novel adjuvant for nucleic acid vaccines, and in particular the present invention provides nucleic acid vaccines that comprise, or are administered in association with PPD. The present invention also provides methods to improve the therapeutic efficacy of nucleic acid vaccines.Type: ApplicationFiled: June 14, 2007Publication date: December 24, 2009Applicant: TRANSGENE S.A.Inventors: Jean-Yves Bonnefoy, Jean-Marc Limacher, Stéphane Paul
-
Patent number: 7618637Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of at least one heat shock protein in combination with one or more defined target antigens. These methods and compositions may be used in the treatment of infectious eases and cancers.Type: GrantFiled: June 13, 2002Date of Patent: November 17, 2009Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James Rothman, F. Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew